natgillin/translations-raw huggingface dataset:
How is Docetaxel Kabi used? 
Kako se zdravilo Docetaxel Kabi uporablja?
This summary was last updated in December 2014. 
Povzetek je bil nazadnje posodobljen decembra 2014.
Protection prevents mortality and reduces infection and disease. 
Zaščita preprečuje smrtnost ter zmanjšuje tveganje okužbe in bolezni.
This will help to protect against the disease. 
To bo živali pomagalo pri zaščiti pred boleznijo.
Protection lasted at least six months after vaccination. 
Zaščita je trajala vsaj šest mesecev po cepljenju.
The laboratory studies showed that the vaccine had its full effect against CSFV by two weeks. 
Laboratorijske študije so pokazale, da je cepivo svoj polni učinek proti KPK doseglo v dveh tednih.
The vaccine is given to pigs from seven weeks of age as a single injection into the muscle. 
Cepivo se daje pujskom, starejšim od sedmih tednov, kot enkratna injekcija v mišico.
The main measure of effectiveness was development of antibodies against E2 protein 14 days after vaccination. 
Glavno merilo učinkovitosti je bil razvoj protiteles proti beljakovini E2 14 dni po cepljenju.
The European Commission granted a marketing authorisation valid throughout the European Union, for Suvaxyn CSF Marker on 10/02/2015. 
Evropska komisija je dovoljenje za promet z zdravilom Suvaxyn CSF Marker, veljavno po vsej Evropski uniji, izdala 10/02/2015.
As CSF is a notifiable disease, it is not possible to conduct standard field studies. 
Ker je KPK bolezen, ki jo je treba obvezno prijaviti, izvedba standardnih terenskih študij ni mogoča.
This disease causes fever, skin lesions, convulsions and often leads to death of the animals. 
Bolezen povzroča povišano telesno temperaturo, kožne lezije in krče ter pogosto vodi k poginu živali.
The purpose of these studies was to establish how long it took for pigs to be fully protected and the length of time protection lasts against CSFV. 
Namen teh študij je bil ugotoviti, po kolikem času je nastopila popolna zaščita prašičev pred virusom KPK in kako dolgo je ta zaščita trajala.
Protection starts two weeks after vaccination and lasts for at least six months. 
Učinkovati začne dva tedna po cepljenju in traja najmanj šest mesecev.
The effectiveness of Suvaxyn CSF Marker was further investigated in a small scale study with 30 eight-week-old piglets. 
Učinkovitost zdravila Suvaxyn CSF Marker so nadalje raziskovali v manjši študiji, v katero je bilo vključenih 30 pujskov, starih osem tednov.
The vaccine is available as a lyophilisate (freeze dried powder) and solvent for injection. 
Cepivo je na voljo je v obliki liofilizata (praška, sušenega z zamrzovanjem) in vehikla za injiciranje.
When the vaccine is given to a healthy pig, the animal's immune system recognises the vaccine virus as ‘foreign' and makes antibodies against it. 
Ko se zdravilo da zdravemu prašiču, imunski sistem živali virus cepiva prepozna kot tujek in začne proti njemu tvoriti protitelesa.
In the future, if the animals are exposed to CSFV, their immune system will be triggered by the virus and be able to respond more quickly. 
Ob morebitni ponovni izpostavitvi živali virusu KPK v prihodnosti bo virus sprožil imunski sistem, ki se bo lahko odzval hitreje.
The field study showed that vaccination with Suvaxyn CSF Marker resulted in 19 out of 20 piglets developing antibodies against E2 protein. 
Terenska študija je pokazala, da je ob cepljenju z zdravilom Suvaxyn CSF Marker 19 od 20 pujskov razvilo protitelesa proti beljakovini E2.
Suvaxyn CSF Marker should not be used to vaccinate sows. 
Zdravilo Suvaxyn CSF Marker se ne sme uporabljati za cepljenje svinj.
Twenty piglets were given Suvaxyn CSF Marker and 10 piglets were given a placebo (dummy) injection. 
20 pujskov je prejelo zdravilo Suvaxyn CSF Marker, 10 pujskov pa injekcijo s placebom (brez zdravilne učinkovine).
Suvaxyn CSF Marker is a vaccine containing bovine viral diarrhoea virus, which can infect pigs but does not normally cause disease in them. 
Zdravilo Suvaxyn CSF Marker je cepivo, ki vsebuje virus goveje virusne driske, s katerim se prašiči lahko okužijo, vendar pri njih običajno ne povzroči bolezni.
The CVMP concluded that the benefits of Suvaxyn CSF Marker exceed the risks for the approved indication and recommended that Suvaxyn CSF Marker be given a marketing authorisation. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Suvaxyn CSF Marker večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
Other information about Suvaxyn CSF Marker: 
Druge informacije o zdravilu Suvaxyn CSF Marker:
This is because if given to pregnant sows it does not prevent them from passing CSFV infection to their offspring but can hide signs of infection in the piglets, allowing them to spread the disease. 
Cepljenje s tem zdravilom namreč ne preprečuje prenašanja okužbe s KPK s svinj na potomce, lahko pa zakrije znake okužbe pri pujskih, zaradi česar lahko ti širijo bolezen.
Suvaxyn CSF Marker is used to protect pigs against outbreaks of classical swine fever, a very severe and highly contagious viral disease of both wild and domestic pigs. 
Zdravilo Suvaxyn CSF Marker se uporablja za zaščito prašičev pred izbruhom klasične prašičje kuge, zelo hude in izjemno nalezljive virusne bolezni, ki prizadene divje in domače prašiče.
What benefit has Suvaxyn CSF Marker shown during the studies? 
Kakšne koristi je zdravilo Suvaxyn CSF Marker izkazalo med študijami?
The vaccine virus in Suvaxyn CSF Marker has been modified so that it will produce the E2 protein, which is part of the outer coat of the closely related virus CSFV, which it provides protection against. 
Virus v cepivu Suvaxyn CSF Marker je bil spremenjen tako, da tvori beljakovino E2, ki je del zunanje ovojnice zelo sorodnega virusa klasične prašičje kuge, proti kateremu cepivo zagotavlja zaščito.
Suvaxyn CSF Marker is a recombinant veterinary vaccine that contains live bovine viral diarrhoea virus (BVDV) which has been modified to replace the envelope (E2) gene of BVDV with the corresponding gene of classical swine fever virus (CSFV). 
Zdravilo Suvaxyn CSF Marker je rekombinantno cepivo za uporabo v veterinarski medicini, ki vsebuje živi virus goveje virusne driske, pri katerem je gen goveje virusne driske, ki kodira beljakovino virusne ovojnice (E2), nadomeščen z ustreznim genom klasične prašičje kuge (KPK).
The withdrawal period for Suvaxyn CSF Marker for pigs is zero days. 
Karenca za zdravilo Suvaxyn CSF Marker pri prašičih je nič dni.
The vaccine has potential marker properties which may allow detection of pigs infected with field CSFV as distinct from Suvaxyn CSF Marker vaccinated pigs, in accordance with the DIVA principle (differentiation of infection from vaccination). 
Cepivo ima morebitne lastnosti markerja, kar lahko v skladu z načelom DIVA (razlikovanje med okuženimi in cepljenimi živalmi) omogoči razlikovanje med živalmi, okuženimi s terenskim virusom KPK, in živalmi, cepljenimi z zdravilom Suvaxyn CSF Marker.
What is the risk associated with Suvaxyn CSF Marker? 
Kakšna tveganja so povezana z zdravilom Suvaxyn CSF Marker?
Why has Suvaxyn CSF Marker been approved? 
Zakaj je bilo zdravilo Suvaxyn CSF Marker odobreno?
There are no known side effects with Suvaxyn CSF Marker when it is used according to the approved indication of the product information. 
Če se zdravilo Suvaxyn CSF Marker uporablja v skladu z odobrenimi indikacijami, navedenimi v informacijah o zdravilu, nima znanih neželenih učinkov.
What is Suvaxyn CSF Marker? 
Kaj je zdravilo Suvaxyn CSF Marker?
Classical swine fever vaccine (live recombinant) 
Suvaxyn CSF Marker cepivo proti klasični prašičji kugi (živi rekombinantni virus)
How has Suvaxyn CSF Marker been studied? 
Kako je bilo zdravilo Suvaxyn CSF Marker raziskano?
What is Suvaxyn CSF Marker used for? 
Za kaj se zdravilo Suvaxyn CSF Marker uporablja?
How does Suvaxyn CSF Marker work? 
Kako zdravilo Suvaxyn CSF Marker deluje?
What is the withdrawal period? 
Kako dolgo traja karenca?
The final opinion was converted into a Decision by the European Commission on 3 August 2009. 
Končno mnenje je bilo spremenjeno v odločbo Evropske komisije dne 3 August 2009.
The application was submitted in the framework of Article 32 of Directive 2001/82/EC, as amended, where the Reference Member State was the United Kingdom and the Concerned Member States were Austria, Belgium, Denmark, France, Germany, Greece, Ireland, Italy, The Netherlands, Portugal and Spain. 
Vloga je bila predložena v skladu s členom 32 Direktive 2001/82/ES, kakor je bila spremenjena, pri čemer je bilo Združeno kraljestvo referenčna država članica, Avstrija, Belgija, Danska, Francija, Nemčija, Grčija, Irska, Italija, Nizozemska, Portugalska in Španija pa zadevne države članice.
The rapporteur and co-rapporteur appointed were: Dr Bruno Urbain and Dr Michael Holzhauser-Alberti, respectively. 
Imenovana poročevalec oziroma soporočevalec sta bila: dr. Bruno Urbain oziroma dr. Michael Holzhauser-Alberti.
The Mutual Recognition Procedure started on 28 February 
Postopek medsebojnega priznavanja se je začel 28. februarja 2008.
3 August 2009 Doc. 
3. avgust 2009 Sklic dok.
Florfenicol is a synthetic broad spectrum antibiotic with a range of activity, including many Gramnegative and Gram-positive organisms. 
Florfenikol je sintetični antibiotik s širokim spektrom delovanja, tudi proti mnogim gramnegativnim in grampozitivnim organizmom.
Oral explanations were given on 16 April 2009. 
Ustna pojasnila so bila podana 16. aprila 2009.
Written explanations were provided by the Marketing Authorisation Holder on 15 January 2009. 
Pisna pojasnila je imetnik dovoljenja za promet z zdravilom predložil 15. januarja 2009.
Based on the evaluation of the rapporteurs' assessment of the currently available data, the CVMP considered that the use of the product as recommended for therapeutic use only does not constitute a risk for the environment. 
Na podlagi ocene poročevalčevega vrednotenja trenutno razpoložljivih podatkov je Odbor za zdravila za uporabo v veterinarski medicini (CVMP) menil, da uporaba zdravila, kot je priporočena samo za terapevtske namene, ne pomeni tveganja za okolje.
However, the CVMP also considered that the wording of the therapeutic indication as authorised in the Reference Member State should be amended to clearly state the limitations of the approved use and avoid incorrect interpretation. 
Vendar pa je CVMP tudi menil, da bi bilo treba besedilo terapevtske indikacije, kot jo je odobrila referenčna država članica, spremeniti, da bi bile v njem jasno navedene omejitve glede odobrene uporabe in bi se izognili nepravilni razlagi.
Due to concerns raised by Germany and The Netherlands during the Mutual Recognition Procedure that Shotaflor 300 mg/ml solution for injection for cattle could present a potential serious risk to the environment, the United Kingdom referred the matter to the EMEA on 31 July 2008 under Article 33(4) of Directive 2001/82/EC. 
Zaradi zadržkov, ki sta jih med postopkom z medsebojnim priznavanjem izrazili Nemčija in Nizozemska, da bi lahko zdravilo Shotaflor 300 mg/ml, raztopina za injiciranje za govedo, pomenilo možno resno tveganje za okolje, je Združeno kraljestvo dne 31. Julija 2008 zadevo napotilo na agencijo EMEA v skladu s členom 33(4) Direktive 2001/82/ES.
OPINION FOLLOWING AN ARTICLE 33 (4)1 REFERRAL FOR SHOTAFLOR 300 MG/ML SOLUTION FOR INJECTION FOR CATTLE International Non-Proprietary Name (INN): Florfenicol 
MNENJE V ZVEZI Z NAPOTITVIJO V SKLADU S ČLENOM 33(4)1 ZA ZDRAVILO SHOTAFLOR 300 MG/ML, RAZTOPINA ZA INJICIRANJE ZA GOVEDO Mednarodno nelastniško ime (INN): florfenikol
The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amended Summary of Product Characteristics and package leaflet in the Annex III. 
Seznam zadevnih imen zdravil je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s spremenjenim povzetkom glavnih značilnosti zdravila in navodilom za uporabo v Dodatku III.
Therefore the Committee adopted an opinion on 14 May 2009 recommending the variation of the Marketing Authorisation in line with the proposed amendments to the Summary of Product Characteristics and package leaflet. 
Zato je Odbor 14. maja 2009 sprejel mnenje, v katerem je priporočil spremembo dovoljenja za promet v skladu s predlaganimi dopolnitvami povzetka glavnih značilnosti zdravila in navodila za uporabo.
The Marketing Authorisation Holder, Virbac S.A., submitted an application via mutual recognition for Shotaflor 300 mg/ml solution for injection for cattle, on the basis of the marketing authorisation granted by the United Kingdom. 
Imetnik dovoljenja za promet z zdravilom, družba Virbac S.A., je po postopku z medsebojnim priznavanjem vložil vlogo za zdravilo Shotaflor 300 mg/ml, raztopina za injiciranje za govedo, na podlagi dovoljenja za promet, ki je bilo odobreno v Združenem kraljestvu.
Ref. EMEA/313852/2009 
: EMEA/562567/2009 Error!
DuoPlavin must not be used during the last three months of pregnancy. 
Zdravilo DuoPlavin se ne sme uporabljati v zadnjih treh mesecih nosečnosti.
The European Commission granted a marketing authorisation valid throughout the EU for DuoPlavin on 15 March 2010. 
Evropska komisija je dovoljenje za promet z zdravilom DuoPlavin, veljavno po vsej Evropski uniji, izdala 15. marca 2010.
The full EPAR for DuoPlavin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo DuoPlavin je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Other information about DuoPlavin: 
Druge informacije o zdravilu DuoPlavin:
This document is a summary of the European Public Assessment Report (EPAR) for DuoPlavin. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo DuoPlavin.
The Committee therefore decided that DuoPlavin's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor je zato zaključil, da so koristi zdravila DuoPlavin večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
For more information about treatment with DuoPlavin, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom DuoPlavin preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What is the risk associated with DuoPlavin? 
Kakšna tveganja so povezana z zdravilom DuoPlavin?
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for DuoPlavin. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo DuoPlavin, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
What benefit has DuoPlavin shown during the studies? 
Kakšne koristi je zdravilo DuoPlavin izkazalo med študijami?
Because the two active substances have been used together for a number of years, the company presented the results of studies showing that the active substances in DuoPlavin are absorbed in the body in the same way when taken in a single tablet as when the two medicines are taken separately. 
Ker se obe zdravilni učinkovini že vrsto let uporabljata sočasno, je družba predstavila rezultate študij, ki kažejo, da se zdravilni učinkovini zdravila DuoPlavin v eni tableti v telesu absorbirata enako, kot če ju bolnik jemlje ločeno.
• patients being treated for heart attack with ST-segment elevation, when the doctor thinks that they would benefit from thrombolytic treatment (treatment to dissolve blood clots). 
• pri bolnikih, ki se zdravijo zaradi srčnega napada z dvigom ST-spojnice, kadar zdravnik meni, da jim bo trombolitično zdravljenje (zdravljenje s ciljem razgradnje krvnih strdkov) koristilo.
The combination of the two active substances has an additive effect, reducing the risk of blood clots forming, more than either medicine alone. 
Kombinacija obeh zdravilnih učinkovin ima aditiven učinek, saj zmanjša tveganje za nastanek krvnih strdkov bolj kot vsako od obeh zdravil posamično.
The most common side effects with DuoPlavin (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising, and bleeding where the skin is punctured. 
Najpogostejši neželeni učinki zdravila DuoPlavin (opaženi pri 1 do 10 bolnikih od 100) so hematomi (kopičenje krvi pod kožo), epistaksa (krvavitve iz nosu), gastrointestinalna hemoragija (krvavitve v želodcu ali črevesju), driska, bolečine v trebuhu, dispepsija (zgaga), podplutbe in krvavitve na mestu vboda v kožo.
DuoPlavin is a medicine that contains two active substances, clopidogrel and acetylsalicylic acid (also known as aspirin). 
DuoPlavin je zdravilo, ki vsebuje dve zdravilni učinkovini, klopidogrel in acetilsalicilno kislino (znano tudi kot aspirin).
DuoPlavin clopidogrel / acetylsalicylic acid 
DuoPlavin klopidogrel/acetilsalicilna kislina
It must not be used in patients who have a disease that is causing bleeding, such as stomach ulcer or bleeding in the brain or in patients with mastocytosis (high blood levels of certain white blood cells called mast cells). 
Ne sme se uporabljati pri bolnikih z obolenji, ki povzročajo krvavitve, kot so želodčne razjede ali možganska krvavitev, ali pri bolnikih z mastocitozo (visokimi ravnmi določenih belih krvničk, imenovanih mastociti).
• patients who have ‘unstable angina' (a severe type of chest pain) or who have had a heart attack with no ‘ST-segment elevation' (an abnormal reading on the ECG or electrocardiogram), including those who are having a stent (a short tube) inserted into an artery to prevent it from closing up; 
• pri bolnikih, ki imajo nestabilno angino pektoris (hudo vrsto bolečine v prsih) ali so imeli srčni napad brez „elevacije ST-spojnice“ (nenormalnega odčitka na elektrokardiogramu ali EKG-ju), ter pri tistih, ki jim je bil v arterijo vstavljen stent (kratka cevka), ki preprečuje, da bi se arterija zamašila;
For the full list of all side effects reported with DuoPlavin, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila DuoPlavin, glejte navodilo za uporabo.
The CHMP noted that DuoPlavin is comparable to clopidogrel and acetylsalicylic acid tablets taken separately, and concluded that combining both active substances in a single DuoPlavin tablet simplifies treatment for patients as they will need to take fewer tablets. 
CHMP je menil, da je zdravilo DuoPlavin primerljivo s tabletami s klopidogrelom in acetilsalicilno kislino, ki se jemljejo ločeno, in zaključil, da kombinacija obeh zdravilnih učinkovin v eni tableti zdravila DuoPlavin poenostavi zdravljenje bolnikov, saj bodo lahko zaužili manj tablet.
DuoPlavin must not be used in people who are hypersensitive (allergic) to clopidogrel, non steroidal anti-inflammatory drugs (such as acetylsalicylic acid) or any of the other ingredients in DuoPlavin. 
Zdravila DuoPlavin ne smejo uporabljati osebe, ki so preobčutljive za (alergične na) klopidogrel, nesteroidna protivnetna zdravila (kot je acetilsalicilna kislina) ali katero koli drugo sestavino zdravila DuoPlavin.
DuoPlavin is used to prevent problems caused by blood clots and hardening of the arteries, such as a heart attack, in adults who are already taking both clopidogrel and acetylsalicylic acid as separate tablets. 
Zdravilo DuoPlavin se uporablja za preprečevanje težav, ki jih povzročajo krvni strdki in zatrditev arterij, kot je srčni napad, pri odraslih, ki že jemljejo klopidogrel in acetilsalicilno kislino.
DuoPlavin is taken as one tablet once a day in place of the clopidogrel and acetylsalicylic acid tablets that the patient has already been taking separately. 
Zdravilo DuoPlavin se jemlje kot ena tableta enkrat na dan namesto tablete s klopidogrelom in tablete z acetilsalicilno kislino, ki ju je bolnik pred tem jemal ločeno.
Why has DuoPlavin been approved? 
Zakaj je bilo zdravilo DuoPlavin odobreno?
DuoPlavin was shown to be comparable to clopidogrel and acetylsalicylic acid taken separately, and can therefore be used in place of the clopidogrel and acetylsalicylic acid tablets that the patients have already been taking. 
Zdravilo DuoPlavin se je izkazalo za primerljivo s klopidogrelom in acetilsalicilno kislino, vzetima ločeno, zato se lahko uporablja namesto tablet s klopidogrelom in acetilsalicilno kislino, ki so jih bolniki jemali doslej.
Both active substances in DuoPlavin, clopidogrel and acetylsalicylic acid, are antiplatelet medicines. 
Obe zdravilni učinkovini zdravila DuoPlavin, klopidogrel in acetilsalicilna kislina, sta „zaviralca agregacije trombocitov“.
How has DuoPlavin been studied? 
Kako je bilo zdravilo DuoPlavin raziskano?
What is DuoPlavin used for? 
Za kaj se zdravilo DuoPlavin uporablja?
How does DuoPlavin work? 
Kako zdravilo DuoPlavin deluje?
How is DuoPlavin used? 
Kako se zdravilo DuoPlavin uporablja?
Further information on Pelmeg can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/pelmeg. 
Nadaljnje informacije o zdravilu Pelmeg so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/pelmeg.
What measures are being taken to ensure the safe and effective use of Pelmeg? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pelmeg?
This means that Pelmeg is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU. 
To pomeni, da je zelo podobno drugemu biološkemu zdravilu („referenčnemu zdravilu“), ki je že odobreno v EU.
An overview of Pelmeg and why it is authorised in the EU 
Pregled zdravila Pelmeg in zakaj je odobreno v EU
The most common side effect with Pelmeg (which may affect more than 1 in 10 people) is pain in the bones. 
Najpogostejši neželeni učinek zdravila Pelmeg (ki se lahko pojavi pri več kot 1 bolniku od 10) je bolečina v kosteh.
What are the risks associated with Pelmeg? 
Kakšna tveganja so povezana z zdravilom Pelmeg?
Why is Pelmeg authorised in the EU? 
Zakaj je zdravilo Pelmeg odobreno v EU?
As for all medicines, data on the use of Pelmeg are continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Pelmeg stalno spremljajo.
Side effects reported with Pelmeg are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Pelmeg, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What is Pelmeg and what is it used for? 
Kaj je zdravilo Pelmeg in za kaj se uporablja?
Other information about Pelmeg 
Druge informacije o zdravilu Pelmeg
What benefits of Pelmeg have been shown in studies? 
Kakšne koristi je zdravilo Pelmeg izkazalo v študijah?
The reference medicine for Pelmeg is Neulasta. 
Referenčno zdravilo za zdravilo Pelmeg je zdravilo Neulasta.
Pelmeg is given as a single dose of 6 mg injected under the skin at least 24 hours after the end of each cycle of chemotherapy (treatment with cancer medicines). 
Zdravilo Pelmeg se daje v obliki enkratnega odmerka v jakosti 6 mg, ki se injicira pod kožo vsaj 24 ur po koncu vsakega ciklusa kemoterapije (zdravljenja z zdravili proti raku).
Pelmeg can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the treatment of cancer or blood disorders. 
Predpisovanje in izdaja zdravila Pelmeg je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem rakavih obolenj ali krvnih bolezni.